Overview · Filed: May 13, 2024Open on UPC Registry
UPC_CFI_145/2024
NOVEL ANTITUMORAL USE OF CABAZITAXEL
InfringementMain Infringement ActionMunich LDInfringementCase Closed
Parties
Claimants
- Sanofi Mature IP(Sanofi Group)
- Sanofi Winthrop Industrie(Sanofi Group)
- Sanofi-Aventis GmbH(Sanofi Group)
- Sanofi Belgium(Sanofi Group)
- Sanofi-Aventis Deutschland GmbH(Sanofi Group)
- Sanofi S.r.l.(Sanofi Group)
- Sanofi B.V.(Sanofi Group)
- Sanofi - Produtos Farmaceuticos Lda(Sanofi Group)
- Sanofi AB(Sanofi Group)
- Sanofi A/S(Sanofi Group)
Reps: Frédéric Chevallier (Herbert Smith Freehills)
Respondents
- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare B.V.
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
Reps: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Judges
- Matthias Zigann
- Alima Zana
- Tobias Pichlmaier
- Carola Wagner
Patents
- EP2493466
- EP 2 493 466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16
Technology area: Pharmaceuticals · Small Molecule
Sector: Pharmaceutical & Medical
Outcome
Procedural onlyProcedural only (no substantive ruling yet)
Filed: May 13, 2024
First decided: —
Language: English